



## Company Overview

Iterum Therapeutics plc is an Ireland-based clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives. These products are aimed at combatting the global crisis of multi-drug resistant (MDR) pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum's first product is a novel anti-infective compound that has demonstrated potent in-vitro activity vs. a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics.

[Sign up here](#) to receive notices about press releases and SEC filings.

## Iterum Therapeutics to Present at the 19th Annual Needham Virtual Healthcare Conference

Apr 9 2020, 4:05 PM EDT

## Iterum Therapeutics Provides Update on Phase 3 Clinical Trials of Sulopenem in Complicated Urinary Tract Infection (cUTI) and Uncomplicated Urinary Tract Infection (uUTI)

Mar 31 2020, 7:00 AM EDT

## Iterum Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results

Mar 12 2020, 6:45 AM EDT

## Stock Overview

Symbol	ITRM
Exchange	Nasdaq
Market Cap	42.97m
Last Price	\$2.89
52-Week	\$1.401 - \$9.3007

04/09/2020 03:53 PM EDT

## Investor Relations

[ir@iterumtx.com](mailto:ir@iterumtx.com)

## Management Team

### Corey N. Fishman

Chief Executive Officer

### Michael Dunne, MD

Chief Scientific Officer

### Judith M. Matthews

Chief Financial Officer

### Benjamin M. Pe

Vice President Operations

### John J. White

Vice President Commercial Planning & Business Development

### Tom Loughman, PhD

Vice President and CMC Head

## Iterum Therapeutics plc

200 S Wacker Drive  
Suite 2550  
Chicago, IL 60606  
USA

## Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.